HC Wainwright Rates Opus Genetics (IRD) buy, $8 Price Target
HC Wainwright maintains a buy rating on IRD, targeting $8 per share, a 93.24% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Opus Genetics, Inc. ($IRD) "buy" with a $8 price target on June 17, 2026.
Since the rating, $IRD is down 8.6% after 1 week, down 19.5% after 1 month and down 5.4% to date (from the $4.06 close on Jun 17, 2026).
IRD
Opus Genetics, Inc.
Key Points
- On June 17, 2026, HC Wainwright reiterated its buy rating on IRD, setting a price target of $8.
- HC Wainwright's $8 price target implies 93.24% upside from Opus Genetics, Inc.'s ($IRD) current $4.14 share price.
- IRD shares are trading around $3.95, with recent insider sales including 1.7 million shares by the Foundation Fighting Blindness.
- Other analysts like Guggenheim and Leerink Partners have also rated IRD as a buy, with targets up to $16.
Get $IRD trade alerts by text
We text you when insiders, Congress or big funds trade $IRD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Opus Genetics, Inc. alert may contain errors. Disclosures
On June 17, 2026, HC Wainwright reaffirmed its buy rating on IRD, setting a price target of $8. The analyst behind the decision, Matthew Caufield, believes in the stock's potential for growth. Currently, IRD shares are trading around $3.95.
Other Institutional Activity in IRD
Several institutional investors have made moves regarding IRD. Caligan Partners LP established a position with 6,075,028 shares valued at approximately $27.6 million. Adage Capital Partners GP, L.L.C. increased its holdings by 4,924,779 shares, bringing its total to 6,029,775 shares worth about $27.4 million. Meanwhile, Millennium Management LLC added 627,882 shares, ending with 2,630,432 shares valued at around $11.97 million.
Opus Genetics, Inc. Stock Down 20.1%
IRD shares are trading near $3.95. While the company lacks a published P/E ratio, the stock's 52-week range and other financial metrics like moving averages are not provided, indicating a need for further financial analysis to assess its volatility and market position.
$IRD price target
Opus Genetics, Inc. daily closes and this analyst's $8 target. Not advice.
Insider Buying and Selling at Opus Genetics, Inc.
Insider transactions have been active at IRD. On May 18, 2026, the Foundation Fighting Blindness Retinal Degeneration Fund sold 1,700,000 shares at an average price of $4.35. Earlier, on April 23, several executives, including Chief Scientific & Development Officer Jayagopal Ashwath and CEO George Magrath, sold shares at prices around $5.19 to $5.24.
Analysts Set New Price Targets
HC Wainwright is not alone in its bullish outlook for IRD. On June 4, 2026, Guggenheim initiated coverage with a buy rating and a $16 target. Leerink Partners also began coverage on May 21, setting a buy rating with a $10 target. The consensus among analysts is positive, with a general buy recommendation and various price targets reflecting confidence in IRD's future prospects.
About IRD
IRD operates in a competitive sector, focusing on innovative solutions. While specific details about its headquarters, CEO, and employee count are not provided, the company's strategic initiatives and market activities suggest a focus on growth and development.
Bottom Line
HC Wainwright's reiteration of a buy rating with an $8 target on IRD reflects optimism in its growth potential. Investors and analysts alike are keeping a close eye on IRD's performance, considering recent institutional activity and insider sales. As with all 13F filings and analyst ratings, these insights are based on past data and expectations, and investors should consider the broader market context.
Related Filing Alerts
Source: HC Wainwright's rating change on $IRD (Jun 17, 2026). Written by software, not financial advice. How we make alerts